The goal of this clinical trial is to test 6 months of aerobic exercise in older adults who are 65 years or older and have mild cognitive impairment (MCI) or probable/possible mild Alzheimer's Disease. The main questions it aims to answer are: * test the effects of aerobic exercise on aerobic fitness, white matter hyperintensity (WMH) volume, and patient-centered outcomes; * identify the best exercise to improve aerobic fitness and reduce non-responses over 6 months; and * examines the mechanisms of aerobic exercise's action on memory in older adults with early AD. Participants will receive 6 months of supervised exercise, undergo cognitive data collection and exercise testing 5 times over a year span, have an MRI brain scan 3 times over a one-year span, and have monthly follow-up discussions on health and wellness.
The purpose of this Phase II, mechanistic Sequential, Multiple Assignment, Randomized Trial (SMART) is to test the effects of 6-month aerobic exercise on aerobic fitness and MRI and plasma biomarkers in community-dwelling older adults with early Alzheimer's disease (AD). The aims are to (I) test the effects of aerobic exercise on aerobic fitness, white matter hyperintensity (WMH) volume, and patient-centered outcomes; (II) identify the best exercise to improve aerobic fitness and reduce non-responses over 6 months; and (III) examines the mechanisms of aerobic exercise's action on memory in older adults with early AD. This trial builds on our previous work showing inter-individual differences in VO2peak responses to moderate-intensity continuous training (MICT); an ability of plasma neurofilament light chain (NfL) to predict cognition; and 6-month MICT maintained memory, reduced WMH, affected plasma p-tau181, and improved physical function, QoL, and caregiver distress. Aerobic exercise is a promising treatment for Alzheimer's disease (AD) and AD-related dementia (ADRD) but has shown mixed effects on cognition, physical function, behavioral and psychological symptoms of dementia (BPSD), quality of life (QoL), and caregiver burden. These findings are likely due to inter-individual differences in aerobic fitness responses, which have long been established in adults using VO2peak and were first reported in AD/ADRD by our team. Most AD/ADRD exercise trials did not measure VO2peak and those that reported large inter-individual differences in VO2peak responses to MICT. Mechanistically, animal studies support aerobic exercise modifying AD's ATN biomarkers (Amyloid-beta \[Aβ\], Tau, and Neurodegeneration), but human studies are few and have conflicting findings. Hence, precision exercise is critical to improving VO2peak responses with alternative interventions (high-intensity interval training (HIIT) or combined aerobic \& resistance exercise (CARE)). Because VO2peak can improve and peak from 3 months of MICT, 3 months is an ideal time to identify MICT non-responders and initiate HIIT or CARE.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
216
Aerobic cycling at a moderate intensity (50-75% of heart rate reserve) for 30-50 minutes, 3 times per week for 3-6 months.
Stretching while seated for 30-50 minutes, 3 times per week for 6 months.
Aerobic cycling at a vigorous intensity (80-90% of heart rate reserve 4-minute bouts with 4-minute recovery intervals) for 40 minutes, 3 times per week for 3 months.
6 full-body strength-building exercises followed by 30 minutes of MICT cycling (described above). Total duration is 60 minutes, 3 times per week for 3 months.
Arizona State University
Phoenix, Arizona, United States
RECRUITINGPeak oxygen consumption
VO2peak will be assessed from the symptom-limited peak cycle-ergometer test
Time frame: measured at 0 and 6 months
White Matter Hyperintensity volume
WMH will be assessed from MRI.
Time frame: measured at 0 and 6 months
Memory
Wechsler Memory Scale - Revised; Logical Memory; score 0-50; higher scores indicate less impairment
Time frame: measured at 0, 6, and 12 months
Physical function
Short Physical Performance Battery: score 0-12; lower scores indicate poorer physical function
Time frame: measured at 0, 3, 6, 9, & 12 months
Behavioral and psychiatric symptoms of dementia (BPSD)
Neuropsychiatric Inventory Questionnaire; symptoms present, if yes, then severity and caregiver distress are reported.
Time frame: measured at 1, 3, 6, 9, & 12 months
Caregiver burden
4-item Zarit Burden Interview: score 0-16; higher scores reflect greater burden
Time frame: measured at 1, 3, 6, 9, & 12 months
Quality of Life (QoL)
Quality of Life - AD: score 0-52; higher scores reflect greater life satisfaction
Time frame: measured at 1, 3, 6, 9, & 12 months
Blood amyloid-beta 42 and 40
20 mL blood sample collection
Time frame: measured at 1, 3, 6, 9, & 12 months
Blood phosphorylated tau 181
20 mL blood sample collection
Time frame: measured at 1, 3, 6, 9, & 12 months
Blood total tau, neurofilament light chain
20 mL blood sample collection
Time frame: measured at 1, 3, 6, 9, & 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.